ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current guidelines for the initial treatment of HIV-1 infection provide a number of options to subjects and providers. Durable improvements in virologic and immunologic parameters are observed in the majority of naive subjects for each of the recommended regimens. As newer treatment strategies and drugs become available it is important to critically assess their role in the management of HIV-1 infection. This study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second-generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen for the initial treatment of HIV-1 infection.